Diametric Capital, LP Point Biopharma Global Inc. Put Options Transaction History

Diametric Capital, LP

  • $162 Million
  • Q2 2024

Put Options

0 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
No transaction found.

Others Institutions Holding PNT

# of Institutions
1
Shares Held
20K
Call Options Held
0
Put Options Held
0
View Full List

About POINT Biopharma Global Inc.

PNT Quotes by TradingView
  • Ticker PNT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 104,025,000
  • Description
  • POINT Biopharma Global Inc., a radiopharmaceutical company, focuses on the development and commercialization of radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate canc...
More about PNT
Track This Portfolio

Track Diametric Capital, LP Portfolio

Follow Diametric Capital, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Diametric Capital, LP, based on Form 13F filings with the SEC.

News

Stay updated on Diametric Capital, LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email